Categories
Global stocks Shares

Domino’s Performs Positive Results for the 2nd Quarter

Sustained strength abroad led us to revisit our international unit growth assumptions, pushing us to the low end of management’s 6%-8% guidance over the next few years (6.4%) and raising our fair value estimate to $410 per share from $386. However, we view the market’s reaction as overblown, with the shares trading up 14.5% at the time of writing against our 6.2% fair value estimate lift. The shares currently trade about 30% ahead of our fair value estimate.

In our view, the most impactful earnings discussion pertained to labor market pressure, with management indicating that restaurant margins (24.5%, up 60 basis points sequentially) were largely attributable to understaffing, as even the largest operators are struggling to attract workers in a historically tight hiring environment. The restaurant workforce remains about 10% smaller than its pre-pandemic level, and operators have increasingly leaned on wage hikes, benefits, signing bonuses, and operational efficiencies to fully staff stores. While we expect the best-capitalized operators with strong restaurant margins (like Domino’s) to best weather the storm, we forecast midterm labor costs 150 basis points higher than 2019 (normalized) levels, at 30.5% of restaurant sales.

The firm’s attention to car-side carryout looks strategically sound, with Domino’s using the channel to compete with quick-service drive-thrus without having to pursue more expensive real estate. The channel offers incremental sales, pushes the firm’s digital mix higher, and requires minimal involvement at the point of sale, alleviating pressure.

Company’s Future Outlook

It is expected that Domino’s to benefit from a shift toward lower cost fulfillment channels like the carryout business (and car side carryout) while continuing to automate noncore tasks like closing tills, managing inventory, and benefiting from optimized labor spending via predictive scheduling. Nonetheless, we remain encouraged by the firm’s long-term upside, with our revised forecast calling for 9.5% average system sales growth, 6% unit growth, and 11.5% EPS growth over the next five years.

Company Profile

Domino’s Pizza is a restaurant operator and franchiser with more than 17,800 stores across 90 countries. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 26 dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for more than 6,800 units in the U.S. and Canada. With roughly $16 billion in 2020 system sales, Domino’s is the largest player in the global pizza market, ahead of Pizza Hut, Papa John’s, and Little Caesars.

(Source: Factset)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Daily Report Financial Markets

USA Market Outlook – 27 July 2021

Categories
Daily Report Financial Markets

USA Market Outlook – 26 July 2021

Categories
Global stocks Shares

American Airlines: Significant Revenue Improvement to $19 FVE in the Second Quarter

Passenger revenue increased 105.8% from the previous quarter, the largest increase we’ve seen from U.S. network carrier this quarter, on a 44.4% increase in capacity, a 29.5% increase in load factors to 77.0% and a 10% increase in yield. These metrics remain 24.6%, 11.1%, and 11.4% below 2019 levels, respectively.

Management said business travel improved from roughly 20% of 2019 levels in March to 45% of 2019 levels in June and that much of the increase in demand was from travel within the West Coast. American has not traditionally had much of a presence in business travel on the West Coast, which suggests that the code sharing alliance that American initiated with Alaska Airlines is expanding American’s relevant market.

Company’s Future Outlook

There may be further upside to American’s share gains within business travel, as the firm initiated a code-sharing agreement with JetBlue, which has substantial share in the Northeast. Management said it expects 2022 CASM to be flat relative to 2019 levels, which is not as aggressive a target as peers have guided to. Since American is a domestically oriented airline and the domestic market has recovered faster than the international market, it is expected that the efficiency gains from restructuring should fall to the bottom line faster for American than for more internationally focused airlines as a larger proportion of the network would be in place in 2022.

Company profile

American Airlines is the world’s largest airline by scheduled revenue passenger miles. The firm’s major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Daily Report Financial Markets

USA Market Outlook – 23 July 2021

Categories
Daily Report Financial Markets

USA Market Outlook – 22 July 2021

Categories
Daily Report Financial Markets

USA Market Outlook – 21 July 2021

Categories
IPO Watch

Industrial SPAC Kensington Capital Acquisition V files for a $260 million IPO

Each warrant authorises the holder to purchase one share of the Company’s Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. 

The offering was expected to close on June 30, 2020, subject to customary closing conditions.

Kensington Capital Acquisition V, a blank check business run by Kensington Capital’s founder and focused on industrials, filed with the SEC on Monday to raise up to $260 million.

The business, situated in Westbury, New York, hopes to generate $260 million by selling 26 million units at $10 each. One share of common stock and one-fifth of a warrant, exercisable at $11.50, are included in each unit. Kensington Capital Acquisition V would have a market value of $325 million at the anticipated deal size.

Company Profile

Kensington Capital Acquisition V was founded in 2021 and plans to list on the NYSE under the symbol KCGI.U. The company filed confidentially on June 10, 2021. UBS Investment Bank is the sole bookrunner on the deal. Kensington Capital Acquisition Corp. II operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

(Source: NASDAQ.com)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Daily Report Financial Markets

USA Market Outlook – 20 July 2021

Categories
ipo IPO Watch

IMV Prices 14.3 M Units of Public Offering at $1.75/Unit

One common share and three-quarters of a common share purchase warrant are included in each Unit. Each Warrant authorises the holder to purchase one common share at a price of US$2.10 per common share for a period of 60 months following the closure of the Offering, subject to adjustment in certain conditions.

The Offering is scheduled to close on or around July 20, 2021, with the common shares underlying the Units and Warrants proposed for listing on the TSX and Nasdaq.

The Corporation plans to use the net proceeds of the Offering to continue clinical development of maveropepimut-S (DPX-Survivac) in DLBCL, breast cancer, ovarian cancer, bladder cancer, and microsatellite instability high (MSI-H), as well as to begin clinical development of a new product, DPX-SurMAGE, in bladder cancer, continuing to develop its patented drug delivery technology (DPX), as well as for other corporate reasons.

Company Profile

Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.

(Source:  RTT News)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.